If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
30 November 2021 A US subsidiary of German skin treatment company Biofrontera has resolved its dispute with Dusa Pharmaceuticals, on the eve of a trial over patents covering a light therapy used to treat skin conditions, called BLU-U.
8 December 2017 The English High Court has sided with Eli Lilly in holding that its UK-related claims in a patent case can be heard together with its European-based arguments in the UK.
30 November 2021 A US subsidiary of German skin treatment company Biofrontera has resolved its dispute with Dusa Pharmaceuticals, on the eve of a trial over patents covering a light therapy used to treat skin conditions, called BLU-U.
8 December 2017 The English High Court has sided with Eli Lilly in holding that its UK-related claims in a patent case can be heard together with its European-based arguments in the UK.
30 November 2021 A US subsidiary of German skin treatment company Biofrontera has resolved its dispute with Dusa Pharmaceuticals, on the eve of a trial over patents covering a light therapy used to treat skin conditions, called BLU-U.
8 December 2017 The English High Court has sided with Eli Lilly in holding that its UK-related claims in a patent case can be heard together with its European-based arguments in the UK.
